Lung Cancer
2-Year Follow-Up Showcases Sotorasib Benefit in KRAS G12C+ NSCLC
April 15, 2022
Article
Longer follow-up data from the phase 1/2 CodeBreaK 100 trial show that patients with KRAS G12C–mutant non–small cell lung cancer experienced improved prolonged overall survival and encouraging response rates with sotorasib.
Certain Biomarkers Tied to Superior Durvalumab/Chemo Performance in Extensive-Stage SCLC
April 12, 2022
Article
Patients with YAP1 and inflamed T-cell expressing extensive-stage small cell lung cancer experienced superior overall survival following treatment with durvalumab and etoposide.
Tiragolumab/Atezolizumab Fails to Improve PFS in Extensive-Stage SCLC
April 09, 2022
Article
An update from the phase 3 SKYSCRAPER-02 trial found that tiragolumab to atezolizumab did not significantly improve progression-free survival in extensive-stage small cell lung cancer.
Selpercatinib Shows Promise in Advanced RET Fusion-Positive NSCLC
April 05, 2022
Article
Patients with metastatic RET fusion–positive non–small cell lung cancer experienced encouraging responses with selpercatinib.
Adjuvant Pembrolizumab Reduces Recurrence Risk in Resectable NSCLC
March 25, 2022
Article
Findings from the KEYNOTE-091 trial showed that patients with non–small cell lung cancer who were treated with pembrolizumab following complete resection and chemotherapy had a 24% decreased risk of recurrence compared with a control arm.
Poziotinib Linked With Promising Response Rates in HER2 Exon 20 Insertion-Mutated NSCLC
March 09, 2022
Article
Frontline treatment with poziotinib yielded promising overall response rates in patients with non–small cell lung cancer and HER2 exon 20 insertion mutations.
Patients With Lung Cancer Demonstrate Superior Resilience in the Face of COVID-19
March 09, 2022
Article
The general population experienced nearly double the amount of anxiety and depression that patients with non–small cell lung cancer reported during the COVID-19 pandemic.
Neoadjuvant Nivolumab Plus Platinum-Doublet Chemotherapy Is Now Approved for Resectable NSCLC
March 07, 2022
Article
Nivolumab combined with chemotherapy is now approved in the resectable non–small cell lung cancer setting.
Neoadjuvant Nivolumab/Chemotherapy Combo Under Priority Review in Resectable NSCLC
March 01, 2022
Article
The FDA has initiated a priority review for neoadjuvant nivolumab plus chemotherapy to treat patients with resectable non–small cell lung cancer.
Adagrasib Under Consideration for FDA Approval for Select KRAS G12C+ NSCLC
February 22, 2022
Article
Adagrasib is currently being considered for approval as a treatment option for previously treated patients with KRAS G12C-mutated non-small cell lung cancer.